glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Combination: Safety & Clinical Guidance – PlexusDx Safety of SGLT2 inhibitors, DPP-4

BPC-157 (Body Protection Compound-157) consists of the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

[5] Safety Profile and Known Risks The safety question around BPC-157 has two distinct dimensions: what the existing data shows, and what it cannot yet rule out

Each temperature change stresses the peptide structure

The effect of oxyntomodulin on body weight and BAT temperature is not evident in mice that lack the GLP-1R highlighting a GLP-1R dependent action

10.1016/j.bbcan.2009.11.004 217 Prez de DiegoR.Sancho-shimizuV.LorenzoL.PuelA.PlancoulaineS.PicardC.et al

_END_INGREDIENTS_ Suggested use: As a dietary supplement, 1 tablet daily on an empty stomach, or as directed by a healthcare professional